The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma
Vaccines (Basel). 2022 May 17;10(5):793. doi: 10.3390/vaccines10050793.
1Department of Gastroenterology, St. Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia.
2Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia.
3Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
4Department of Epidemiology and Preventative Medicine, Monash University, Clayton, VIC 3800, Australia.
Abstract
Over 1.5 million preventable new hepatitis B infections continue to occur each year and there are an estimated 296 million people living with chronic hepatitis B infection worldwide, resulting in more than 820,000 deaths annually due to liver cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B vaccination remains the cornerstone of public health policy to prevent HCC and a vital component of the global hepatitis B elimination response. The WHO has set a 90% vaccination target to achieve hepatitis B elimination by 2030; however, there is wide variability in reported birth dose coverage, with global coverage at only 42%. In this review, we outline the global trends in hepatitis B vaccination coverage and the impact of hepatitis B vaccination on HCC incidence and discuss the challenges and enabling factors for achieving WHO 2030 hepatitis B vaccination coverage targets.